RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > CA Congressman Seeks More FDA Outreach for Biotech Start-Ups

CA Congressman Seeks More FDA Outreach for Biotech Start-Ups

Posted 09 December 2016 | By Zachary Brennan 

CA Congressman Seeks More FDA Outreach for Biotech Start-Ups

Rep. Eric Swalwell (D-CA) on Friday sent a letter to US Food and Drug Administration (FDA) Commissioner Robert Califf seeking further assistance for start-up biotechnology companies in the Bay Area.

Swalwell said several companies have expressed their concerns on “the complexity and length of the regulatory process” that many do not have the resources to navigate. He also said the companies are seeking a local San Francisco Bay Area FDA office to provide face-to-face discussions on the regulations and science around drug development.

While recognizing that there are FDA offices in the region, Swalwell says they are primarily focused on regulating imports and “the lack of awareness of their existence shows more FDA outreach to the community is necessary.”

Letter

 

© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe